CROSSJECT (EPA:ALCJ) | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 06/12/2024 at 07:30, 5 months 9 days ago

Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord
Nomination de Dan Chiche, MD en tant que Directeur Médical Amérique du Nord chez Crossject, renforçant l'équipe dirigeante et la présence aux États-Unis pour lancer ZEPIZURE en 2025

Amérique Du Nord Crossject ZEPIZURE Dan Chiche Directeur Médical
BRIEF

published on 06/04/2024 at 19:35, 5 months 16 days ago

Crossject annonce la clôture réussie d'une offre de droits de 8 millions d'euros

Approbation De La FDA Offre De Droits ZEPIZURE® Projet Croisé Traitement De L'épilepsie
BRIEF

published on 06/04/2024 at 19:35, 5 months 16 days ago

Crossject Announces Successful Closing of €8 Million Rights Offering

FDA Approval Rights Offering Crossject ZEPIZURE® Epilepsy Treatment
PRESS RELEASE

published on 06/04/2024 at 19:30, 5 months 16 days ago

Crossject annonce le vif succès de son augmentation de capital de 8 millions d’euros
Crossject annonce le vif succès de son augmentation de capital de 8 millions d'euros pour le développement de ZEPIZURE®. Opération avec maintien du droit préférentiel de souscription et soutien de Gemmes Venture

FDA Augmentation De Capital Crossject ZEPIZURE Gemmes Venture
PRESS RELEASE

published on 06/04/2024 at 19:30, 5 months 16 days ago

Crossject announces highly successful closing of its €8 million rights offering
Crossject successfully closes €8 million rights offering, securing funding for ZEPIZURE® development and FDA approval. Gemmes Venture remains a key supporter

FDA Approval Rights Offering Crossject ZEPIZURE® Gemmes Venture
BRIEF

published on 05/30/2024 at 10:35, 5 months 22 days ago

Crossject : Publication de Données Cliniques sur ZEPIZURE®

Crossject ZEPIZURE® Neurology And Therapy Midazolam Injection Sans Aiguille
BRIEF

published on 05/30/2024 at 10:35, 5 months 22 days ago

Crossject: Publication of Clinical Data on ZEPIZURE®

Crossject ZEPIZURE® Neurology And Therapy Midazolam Needle-free Injection
PRESS RELEASE

published on 05/30/2024 at 10:30, 5 months 22 days ago

Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
Crossject announces publication of clinical data on ZEPIZURE in Neurology and Therapy, highlighting bioequivalence versus Dormicum, early onset, and low variability

Clinical Data Crossject Neurology And Therapy ZEPIZURE Needle-free Auto-injector
PRESS RELEASE

published on 05/30/2024 at 10:30, 5 months 22 days ago

Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and Therapy
Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and Therapy, démontrant une bioéquivalence à Dormicum® pour traiter les crises d'épilepsie de manière plus efficace et sécurisée

Sécurité Crossject Neurology And Therapy ZEPIZURE Bioéquivalence

Accesswire

Published on 11/21/2024 at 12:00, 54 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 54 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 24 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 51 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 54 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 19 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 39 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 47 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 54 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 24 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 56 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 56 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 56 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 46 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 34 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE